Vaccine process technology—A decade of progress

Author(s)Buckland, Barry
Author(s)Sanyal, Gautam
Author(s)Ranheim, Todd
Author(s)Pollard, David
Author(s)Searles, Jim A.
Author(s)Behrens, Sue
Author(s)Pluschkell, Stefanie
Author(s)Josefsberg, Jessica
Author(s)Roberts, Christopher J.
Date Accessioned2024-06-04T18:05:27Z
Date Available2024-06-04T18:05:27Z
Publication Date2024-05-06
DescriptionThis article was originally published in Biotechnology and Bioengineering. The version of record is available at: https://doi.org/10.1002/bit.28703. © 2024 The Authors. Biotechnology and Bioengineering published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
AbstractIn the past decade, new approaches to the discovery and development of vaccines have transformed the field. Advances during the COVID-19 pandemic allowed the production of billions of vaccine doses per year using novel platforms such as messenger RNA and viral vectors. Improvements in the analytical toolbox, equipment, and bioprocess technology have made it possible to achieve both unprecedented speed in vaccine development and scale of vaccine manufacturing. Macromolecular structure-function characterization technologies, combined with improved modeling and data analysis, enable quantitative evaluation of vaccine formulations at single-particle resolution and guided design of vaccine drug substances and drug products. These advances play a major role in precise assessment of critical quality attributes of vaccines delivered by newer platforms. Innovations in label-free and immunoassay technologies aid in the characterization of antigenic sites and the development of robust in vitro potency assays. These methods, along with molecular techniques such as next-generation sequencing, will accelerate characterization and release of vaccines delivered by all platforms. Process analytical technologies for real-time monitoring and optimization of process steps enable the implementation of quality-by-design principles and faster release of vaccine products. In the next decade, the field of vaccine discovery and development will continue to advance, bringing together new technologies, methods, and platforms to improve human health.
SponsorStacey Tobin, PhD, provided editorial support in the preparation of this manuscript, with compensation from NIIMBL. Preparation of this article was supported by funding from the U.S. Department of Commerce, National Institute of Standards and Technology, through Cooperative Agreements 70NANB17H002, 70NANB21H086, and 70NANB21H085. This publication is based on research funded in part by the Bill & Melinda gates Foundation under grant #INV-038807. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation.
CitationBuckland, B., Sanyal, G., Ranheim, T., Pollard, D., Searles, J. A., Behrens, S., Pluschkell, S., Josefsberg, J., & Roberts, C. J. (2024). Vaccine process technology—A decade of progress. Biotechnology and Bioengineering, 1–32. https://doi.org/10.1002/bit.28703
URLhttps://udspace.udel.edu/handle/19716/34447
Languageen_US
PublisherBiotechnology and Bioengineering
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
Keywordsanalytics
Keywordscell culture
Keywordslipid nanoparticle
Keywordsmanufacturing
KeywordsmRNA
Keywordsvaccine characterization
TitleVaccine process technology—A decade of progress
TypeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Vaccine process technology—A decade of progress.pdf
Size:
4.07 MB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.22 KB
Format:
Item-specific license agreed upon to submission
Description: